AU2001281487A1 - 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors - Google Patents
2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitorsInfo
- Publication number
- AU2001281487A1 AU2001281487A1 AU2001281487A AU8148701A AU2001281487A1 AU 2001281487 A1 AU2001281487 A1 AU 2001281487A1 AU 2001281487 A AU2001281487 A AU 2001281487A AU 8148701 A AU8148701 A AU 8148701A AU 2001281487 A1 AU2001281487 A1 AU 2001281487A1
- Authority
- AU
- Australia
- Prior art keywords
- gsk3
- inhibitors
- beta
- amino
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00400800 | 2000-03-23 | ||
EP00400800A EP1136482A1 (en) | 2000-03-23 | 2000-03-23 | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
PCT/EP2001/003640 WO2001070729A1 (en) | 2000-03-23 | 2001-03-22 | 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001281487A1 true AU2001281487A1 (en) | 2001-10-03 |
Family
ID=8173604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001281487A Abandoned AU2001281487A1 (en) | 2000-03-23 | 2001-03-22 | 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
Country Status (16)
Country | Link |
---|---|
US (2) | US6844335B2 (en) |
EP (2) | EP1136482A1 (en) |
JP (1) | JP4778657B2 (en) |
KR (1) | KR100820543B1 (en) |
CN (2) | CN1247567C (en) |
AR (1) | AR028280A1 (en) |
AT (1) | ATE380806T1 (en) |
AU (1) | AU2001281487A1 (en) |
CA (1) | CA2401241C (en) |
CY (1) | CY1107236T1 (en) |
DE (1) | DE60131844T2 (en) |
DK (1) | DK1276738T3 (en) |
ES (1) | ES2296783T3 (en) |
PT (1) | PT1276738E (en) |
SI (1) | SI1276738T1 (en) |
WO (1) | WO2001070729A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR023052A1 (en) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | DERIVATIVES OF PIRIMIDONA |
EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
SE518184C2 (en) | 2000-03-31 | 2002-09-03 | Perstorp Flooring Ab | Floor covering material comprising disc-shaped floor elements which are joined together by means of interconnecting means |
HUP0300927A2 (en) | 2000-04-26 | 2003-07-28 | Eisai Co., Ltd. | Medicinal compositions promoting bowel movement, containing new pyrimidine derivatives |
WO2003037888A1 (en) | 2001-09-21 | 2003-05-08 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
AU2002337498B2 (en) | 2001-09-21 | 2006-08-10 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
TWI301834B (en) * | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
TWI330183B (en) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
EA009027B1 (en) | 2002-12-16 | 2007-10-26 | Мицубиси Фарма Корпорейшн | 3-substituted-4-pirimidone derivatives |
EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
EP1460075A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives |
CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
CN1867560A (en) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20070117818A1 (en) * | 2004-02-04 | 2007-05-24 | Masaichi Hasegawa | Pyrimidinone compounds useful as kinase inhibitors |
UA85871C2 (en) | 2004-03-15 | 2009-03-10 | Такеда Фармасьютікал Компані Лімітед | Dipeptidyl peptidase inhibitors |
AU2005262925B2 (en) * | 2004-07-09 | 2011-01-20 | Agency For Science, Technology And Research | Modulation of GSK-3beta and method of treating proliferative disorders |
AR050865A1 (en) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | DERIVATIVES OF 2- MORFOLINO-4-PIRIMIDONA |
DK1805164T3 (en) * | 2004-09-29 | 2011-05-16 | Mitsubishi Tanabe Pharma Corp | 6- (pyridinyl) -4-pyrimidone derivatives as inhibitors of TAU 1 orotein kinase |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20080207594A1 (en) | 2005-05-04 | 2008-08-28 | Davelogen Aktiengesellschaft | Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
WO2007035629A2 (en) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
KR20090052884A (en) * | 2006-08-23 | 2009-05-26 | 화이자 프로덕츠 인크. | Pyrimidone compounds as gsk-3 inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
AR076014A1 (en) * | 2009-04-02 | 2011-05-11 | Sanofi Aventis | DERIVATIVES OF 3- (1,4) OXAZEPAN -4-PIRIMIDONA |
US9006232B2 (en) | 2009-08-13 | 2015-04-14 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives |
US8940738B2 (en) | 2009-08-13 | 2015-01-27 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone compounds |
EP3741375A1 (en) | 2014-07-17 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
US11331313B2 (en) | 2017-05-22 | 2022-05-17 | Whitehead Institute For Biomedical Research | KCC2 expression enhancing compounds and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4935631B1 (en) | 1970-12-28 | 1974-09-25 | ||
JPS4935633B1 (en) | 1970-12-30 | 1974-09-25 | ||
JPS559099B2 (en) * | 1972-08-07 | 1980-03-07 | ||
JPS4935633A (en) | 1972-08-09 | 1974-04-02 | ||
US4460589A (en) * | 1980-10-03 | 1984-07-17 | The Upjohn Company | Process for treating hypertension |
TW229142B (en) * | 1992-04-15 | 1994-09-01 | Nissan Detrochem Corp | |
US6153618A (en) * | 1996-10-11 | 2000-11-28 | Chiron Corporation | Inhibitors of glycogen synthase 3 kinase |
TW520362B (en) * | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
AU735901C (en) * | 1996-12-05 | 2004-02-12 | Amgen, Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
AR023052A1 (en) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | DERIVATIVES OF PIRIMIDONA |
EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
-
2000
- 2000-03-23 EP EP00400800A patent/EP1136482A1/en not_active Withdrawn
-
2001
- 2001-03-22 SI SI200130806T patent/SI1276738T1/en unknown
- 2001-03-22 DE DE60131844T patent/DE60131844T2/en not_active Expired - Lifetime
- 2001-03-22 KR KR1020027012431A patent/KR100820543B1/en not_active IP Right Cessation
- 2001-03-22 CN CNB018069916A patent/CN1247567C/en not_active Expired - Fee Related
- 2001-03-22 CA CA2401241A patent/CA2401241C/en not_active Expired - Fee Related
- 2001-03-22 WO PCT/EP2001/003640 patent/WO2001070729A1/en active IP Right Grant
- 2001-03-22 JP JP2001568932A patent/JP4778657B2/en not_active Expired - Fee Related
- 2001-03-22 PT PT01959921T patent/PT1276738E/en unknown
- 2001-03-22 CN CNA2006100061354A patent/CN1891220A/en active Pending
- 2001-03-22 AU AU2001281487A patent/AU2001281487A1/en not_active Abandoned
- 2001-03-22 AT AT01959921T patent/ATE380806T1/en active
- 2001-03-22 US US10/221,598 patent/US6844335B2/en not_active Expired - Fee Related
- 2001-03-22 ES ES01959921T patent/ES2296783T3/en not_active Expired - Lifetime
- 2001-03-22 DK DK01959921T patent/DK1276738T3/en active
- 2001-03-22 EP EP01959921A patent/EP1276738B8/en not_active Expired - Lifetime
- 2001-03-23 AR ARP010101372A patent/AR028280A1/en active IP Right Grant
-
2005
- 2005-01-13 US US11/035,264 patent/US7378413B2/en not_active Expired - Fee Related
-
2008
- 2008-03-07 CY CY20081100270T patent/CY1107236T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CY1107236T1 (en) | 2012-05-23 |
DE60131844D1 (en) | 2008-01-24 |
PT1276738E (en) | 2008-02-28 |
EP1276738A1 (en) | 2003-01-22 |
WO2001070729A1 (en) | 2001-09-27 |
ATE380806T1 (en) | 2007-12-15 |
JP2003528095A (en) | 2003-09-24 |
KR20020093848A (en) | 2002-12-16 |
DE60131844T2 (en) | 2008-11-27 |
US7378413B2 (en) | 2008-05-27 |
EP1136482A1 (en) | 2001-09-26 |
CN1891220A (en) | 2007-01-10 |
SI1276738T1 (en) | 2008-06-30 |
US20030187004A1 (en) | 2003-10-02 |
EP1276738B8 (en) | 2008-02-20 |
CN1247567C (en) | 2006-03-29 |
DK1276738T3 (en) | 2008-04-21 |
CA2401241A1 (en) | 2001-09-27 |
JP4778657B2 (en) | 2011-09-21 |
US20050130998A1 (en) | 2005-06-16 |
KR100820543B1 (en) | 2008-04-07 |
ES2296783T3 (en) | 2008-05-01 |
CA2401241C (en) | 2011-11-29 |
US6844335B2 (en) | 2005-01-18 |
EP1276738B1 (en) | 2007-12-12 |
CN1419552A (en) | 2003-05-21 |
AR028280A1 (en) | 2003-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1276738B8 (en) | 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | |
HK1041407A1 (en) | Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors. | |
NL300242I1 (en) | Mega-carboxyaryl substituted diphenylureas as well as kinase inhibitors. | |
AU2001258771A1 (en) | -secretase inhibitors | |
NO20021239L (en) | Pteridinones as kinase inhibitors | |
AU2001296961A1 (en) | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors | |
AU6471300A (en) | P38map kinase inhibitors | |
SI1686119T1 (en) | Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors | |
AU2001237041A1 (en) | Kinase inhibitors | |
AU4882101A (en) | Mmp-12 inhibitors | |
HK1046278A1 (en) | Pyrazolobenzodiazepines as cdk2 inhibitors. | |
HK1054034A1 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors. | |
AU2001284242A1 (en) | Substituted pyrimidines as selective cyclooxygenase-2 inhibitors | |
AU2001262150A1 (en) | 2-(nitrogen-heterocyclic)pyrimidone derivatives | |
AU2002224038A1 (en) | Benzimidazole derivatives | |
AU2002216314A1 (en) | Heterocyclic angiogenesis inhibitors | |
AU1597201A (en) | Pyrrolecarbonylimino derivatives as naaladase inhibitors | |
NO20016201D0 (en) | Tienopyrimidines as phosphodiesterase inhibitors | |
AU2002234010A1 (en) | Benzamidine derivatives | |
AU2002213978A1 (en) | Substituted C-cyclohexylmethylamine derivatives | |
AU3703499A (en) | Substituted indolinones as kinase inhibitors | |
AU2001258841A1 (en) | Heterocyclic compounds | |
AU2001289937A1 (en) | Substituted 1-aminobutan-3-ol derivatives | |
AU3235100A (en) | Prothease inhibitors | |
DK1222193T3 (en) | Imidazole derivatives as phosphodiesterase VII inhibitors |